Structure / Market Size The US Sector $ 12 billion valued pharmaceutical industry in India is expected to grow at an compound annual growth rate (CAGR) of 10-11 per cent. The industry spends around 18 per cent of its revenue on research and development (R&D).
Air fresheners which are used for clean refreshing house or car may smells sweet but very few people understand how bad air fresheners are for their health. Science has confirmed that though air freshener smells sweet but they may cause lung cancer. People with asthma or allergies may want to avoid air fresheners and other chemicals used to spread fragrant scents through their homes, and their doctors should be aware of the hazards.
The Indian drug industry could make huge gains as over $70 billion worth of drugs are expected to go off patent in the US, the world’s largest pharma market, in the next three years.
Ahmedabad based Contract Research and Manufacturing Services (CRAMS) major Dishman Pharmaceuticals and Chemicals Ltd has entered into a strategic alliance with California based biotechnology firm Codexis, Inc. that will allow Dishman to use of Codexis' proprietary enzymatic biocatalysis technology to manufacture intermediates and active pharmaceutical intermediates (APIs).
Dishman Pharmaceuticals & Chemicals Ltd, a contract research & manufacturing services (CRAM) major, received the US Food and Drug Administration (USFDA) nod for producing Active Pharmaceutical Ingredients (API) at its Naroda facility here.
Dishman Chemicals and Pharmaceuticals, the Ahmedabad-based leading player in the contract research and manufacturing services (Crams) space, is expecting growth of about 20% in the segment starting next fiscal.
Few outside the recently developed township of Baddi in Himachal Pradesh will know Arun Rawat or his drug manufacturing company Kanha Biogenetic Laboratories. But this first-generation entrepreneur, who ventured into the drug-making business just five years ago, produces medicines for such majors as Wockhardt, Ajanta Pharma and Ind-Swift, to name a few.
For the pharmaceutical sector, 2009 was a year when Indian manufacturing capabilities took centre stage. For the first time, global pharmaceutical giants like Pfizer and GlaxoSmithKline (GSK) came shopping for Indian manufacturers. Pharmaquest.biz recaps some of biggest inbound pharma deals this year.
Drug maker scouting for Indian companies specializing in therapy segments such as nephrology and urology
India's pharmaceutical sector has stepped up its research & development expenditure in a bid to capture a larger market share in highly regulated and emerging markets.
To reduce over dependence on the private sector for the H1N1 drug, Oseltamivir, the government could soon start scouting for options among the public sector drug manufacturers, with ability to manufacture the antiviral.
Orchid Chemicals & Pharmaceuticals has agreed to sell its injectables business to the US-based Hospira for around $400 million (Rs 1,850 crore), a valuation that represents a 20% premium to the Chennai-based firm’s market value and greatly boosts its financial flexibility.
Gujarat-based pharma companies are turning homewards, as their honeymoon period in the tax-free havens of hill states like Himachal Pradesh and Uttarakhand ends in March 2010.
Pharmintech, the international exhibition for technology, materials and services for the processing and packaging of pharmaceutical, personal care and nutraceutical products is scheduled to take place at BolognaFiere from May 12 to 14 2010.
Pharma companies attempt to formulate guidelines to self regulate the widely prevalent practice of wooing doctors by giving lucrative gifts, has run into trouble.
Dishman Pharmaceuticals and Chemicals Ltd has formed a joint venture company to manufacture active pharmaceutical ingredients (API) in Saudi Arabia with three partners and expects to complete work on the facility in 15 months time.
A group of companies from Germany are scouting for partners in the domestic pharma industry for opportunities in areas of research and development, production and sales and distribution. The group includes Orgentis Chemicals Ltd, Organica Fine Chemicals, Synthon Chemicals and biotech company c-Lecta, which are in talks with some leading Indian pharma companies to forge R&D partnerships.
Bangalore-based biopharmaceutical start-up Biovel Lifesciences is looking to exit from the life sciences space and is keen for an early outright buyout. Biovel has been in dialogue with several companies including Ranbaxy, Avesthagen, Shantha Biotechnics Ltd and Orchid Chemicals, it is learnt.
The assurance of cutting greenhouse gas emissions by China a source of cheap raw material has sent jitters across the pharmaceutical industry which apprehends that it will lead to drug rates shooting up.
Ranbaxy Laboratories exclusive launch of generic anti-herpes Valtrex (valacyclovir hydrochloride) tablets in the US will help a listed Indian drug company, Hyderabad-based Avon Organics.